Showing results (51-60 of 140) with videos related to
Sort By:
Pageof 14
Cancer|May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibodyBrian H Kushner, Shakeel Modak, Ellen M Basu, et al.Cancer|September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literatureBrian H Kushner, Shakeel Modak, Kim Kramer, et al.Journal of Hematology & Oncology|November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trialBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.JAMA Oncology|October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical TrialBrian H Kushner, Irene Y Cheung, Shakeel Modak, et al.International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation TherapyThomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.Pediatric Blood & Cancer|June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With NeuroblastomaWei Wei, Maggie Eidson Fader, Brian H Kushner, et al.Pediatric Blood & Cancer|January 28, 2021
Mandibular metastases in neuroblastoma: Outcomes and dental sequelaeAnnu Singh, Shakeel Modak, Armand K Solano, et al.Oncoimmunology|November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survivalIrene Y Cheung, Brian H Kushner, Shakeel Modak, et al.International Journal of Radiation Oncology, Biology, Physics|July 31, 2016
Local Control With 21-Gy Radiation Therapy for High-Risk NeuroblastomaDana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.Pediatric Blood & Cancer|February 23, 2018
Dose-escalation is needed for gross disease in high-risk neuroblastomaDana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.Pageof 14